Rituximab biosimilar - Pfizer

Drug Profile

Rituximab biosimilar - Pfizer

Alternative Names: PF-05280586; PF-5280586

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Follicular lymphoma
  • Phase I/II Rheumatoid arthritis

Most Recent Events

  • 19 Apr 2018 Pfizer completes the REFLECTIONS phase III trial in Follicular lymphoma (First-line therapy, In the elderly, In adults) in USA, Puerto Rico, Spain, Portugal, Romania, Belgium, Germany, Austria, Belarus, Croatia, France, Italy, Japan, Poland, Russia, South Africa, South Korea, Switzerland, Thailand, Turkey, Ukraine, United Kingdom, Philippines, Peru, Mexico, Lebanon, India, Greece, Georgia, Brazil (IV) (NCT02213263) (EudraCT2014-000132-41)
  • 30 Jan 2018 Phase III development is ongoing in Follicular lymphoma in Belarus, Croatia, France, Italy, Japan, South Korea, Poland, Russia, South Africa, Switzerland, Thailand, Turkey, Ukraine and United Kingdom (Pfizer pipeline, January 2018)
  • 07 Oct 2016 Safety, pharmacokinetic and pharmacodynamic results from the phase I/II trial in Rheumatoid arthritis were presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top